Androgen-Deprivation Therapy plus Radiation Therapy for Prostate Cancer

Level 1 evidence indicates that, among patients with intermediate- and high-risk clinically localized prostate cancer, those who received external-beam radiation therapy (RT) plus androgen-deprivation therapy (ADT) survived longer overall than patients who received RT alone (JW Oncol Hematol Jan 22 2008). To further assess the role of RT in prostate cancer, Scandinavian investigators conducted a phase III randomized trial of ADT with or without RT that involved 875 patients (age, <76) who had locally advanced disease (T1b–T2, G2–G3, or T3N0M0), good performance status, life expectancy >10 years, no evidence of metastases or nodal disease, and prostate-specific antigen (PSA) level ≤70 ng/mL.

All patients received ADT with a luteinizing hormon…